LSE Research Proposal Example: Blood bank coordinator to transfusion safety policy (Score 93)

Transfusion-related adverse events remain a measurable source of preventable harm in hospital settings across high-income countries. Despite decades of technical standardisation in blood component preparation, the policy architecture governing how hospitals translate national haemovigilance requirements into ward-level practice is comparatively under-examined. Regulatory frameworks differ substantially between jurisdictions: some rely on mandatory incident reporting with public disclosure, others on voluntary sentinel surveillance, and others still on accreditation-linked audit cycles. Whether these structural differences in compliance design are associated with variation in reported adverse transfusion event rates is a question that sits at the intersection of health policy and implementation research, yet it has received less systematic attention than the clinical and laboratory dimensions of transfusion safety. This proposal addresses that gap through three related research questions. First, to what extent do differences in the regulatory design of national haemovigilance systems — specifically the mandatory versus voluntary character of reporting obligations — correlate with variation in serious adverse transfusion event rates across comparable high-income health systems? Second, what mechanisms do hospital transfusion committees identify as the primary drivers of frontline compliance with transfusion safety protocols, and do these mechanisms align with the assumptions embedded in national regulatory frameworks? Third, where misalignment between regulatory design and reported compliance mechanisms exists, what policy instruments do the comparative cases suggest as candidates for closing that gap? The rationale for bounding the study to high-income comparators is methodological rather than normative: data comparability across haemovigilance reporting systems is substantially higher within this group, and the ISBT and SHOT annual reports provide a partially harmonised baseline from which cross-national comparison becomes tractable at MSc level. Two bodies of scholarship are directly relevant. The first is the haemovigilance and patient safety literature, which has documented the epidemiology of transfusion-related harm with increasing precision since the establishment of national reporting systems in France, the United Kingdom, and the Netherlands in the 1990s. Studies drawing on SHOT data and comparable European haemovigilance reports have identified transfusion of incorrect blood component and transfusion-associated circulatory overload as persistently high-frequency adverse event categories. This literature is technically detailed but tends to treat the regulatory environment as a background condition rather than an explanatory variable: it asks what goes wrong and how often, not whether the governance structure around reporting shapes what gets counted and acted upon. The second body of work is the health policy and regulatory governance literature, which has examined compliance behaviour in hospital settings across a range of patient safety domains — surgical checklists, medication error reporting, infection control — using frameworks drawn from principal-agent theory and implementation science. Researchers including Braithwaite and colleagues in the broader patient safety field, and Faden and colleagues in quality improvement, have argued that the design of accountability relationships between regulators, hospital management, and frontline clinicians shapes whether safety reporting functions as a learning mechanism or a liability-management exercise. However, this governance literature has rarely been applied specifically to transfusion safety, where the technical specificity of blood component management creates compliance dynamics that may differ from general medication safety. The gap, as this proposal frames it, is the absence of a study that brings these two literatures into direct contact: one that uses cross-national variation in haemovigilance regulatory design as the independent variable and examines both reported event rates and the compliance mechanisms identified by practitioners as the dependent and mediating variables respectively. Existing comparative work has tended to describe system architectures descriptively rather than testing whether design features are associated with measurable differences in outcomes or practitioner behaviour. The study will proceed in two phases. Phase one is a structured cross-national comparison of haemovigilance regulatory frameworks across four to six high-income jurisdictions, provisionally including the United Kingdom, France, the Netherlands, Australia, and Canada. For each jurisdiction, I will code the regulatory design along three dimensions derived from the compliance literature: whether adverse event reporting is mandatory or voluntary; whether reported data are publicly disclosed at the institutional level; and whether haemovigilance compliance is linked to hospital accreditation or licensing. Annual serious adverse event rates per 100,000 units transfused will be drawn from publicly available national haemovigilance reports for the most recent five-year period for which comparable data exist. The unit of analysis is the national system; the comparison is small-n and does not support causal inference, but it can identify whether variation in regulatory design co-varies with outcome variation in a pattern that warrants further investigation. Phase two will involve semi-structured interviews with transfusion practitioners and hospital transfusion committee members in the United Kingdom, using purposive sampling to include participants from NHS trusts of varying size and organisational complexity. The target sample is twelve to sixteen participants, sufficient for thematic saturation in a focused policy study at this level. Interview questions will probe the mechanisms through which practitioners understand compliance obligations, the role of SHOT reporting in their institutional practice, and their perception of whether regulatory requirements function as learning prompts or administrative burdens. Thematic analysis following a framework approach will be used to identify compliance mechanism categories, which will then be mapped against the regulatory design features coded in phase one. The choice of mixed sequential design — quantitative comparison followed by qualitative mechanism tracing — is appropriate because the first phase identifies the pattern requiring explanation and the second phase probes the mechanisms that the quantitative data cannot resolve. The design is proportionate to MSc scope because phase one relies entirely on publicly available documents and the phase two interview sample is small and geographically concentrated. All phase one data sources are publicly available: national haemovigilance annual reports are published by SHOT, the French Agence Nationale de Sécurité du Médicament, the Dutch TRIP foundation, the Australian and New Zealand Society of Blood Transfusion, and Canadian Blood Services. No data access agreements are required for this phase. Phase two interviews will require NHS Health Research Authority ethical review. Given that participants are NHS professionals and no patient data are involved, this study would likely fall within the category of service evaluation or research involving professionals, and HRA guidance suggests a proportionate review pathway. Informed consent, data anonymisation, and secure storage protocols will be implemented in accordance with LSE research ethics requirements. A key risk is recruitment: transfusion practitioners are a specialist group with significant clinical workload. A contingency plan involves reducing the sample to ten participants and supplementing with analysis of published transfusion committee audit reports, which are available through NHS England's Getting It Right First Time programme. The provisional timeline allocates the first term to phase one data collection and coding, the second term to interview fieldwork and analysis, and the dissertation writing period to integration and write-up. This is a standard MSc dissertation schedule and does not require fieldwork outside the United Kingdom. The LSE Department of Health Policy hosts research on regulatory governance, implementation, and health system performance that is directly relevant to this proposal's framing. The department's engagement with comparative health system analysis and its methodological emphasis on policy-relevant empirical work aligns with the study's design. LSE's library access to haemovigilance grey literature and comparative health system databases, including the WHO Global Health Observatory and the OECD Health Statistics portal, provides the secondary data infrastructure the study requires. The MSc Health Policy programme's methods training in qualitative analysis and comparative policy research equips the student to execute both phases within the degree timeline. This proposal does not name a specific supervisor, as supervisor availability is subject to departmental confirmation; the research sits within the department's documented interests in patient safety governance and health system regulation.